Average Ratings 0 Ratings

Total
ease
features
design
support

No User Reviews. Be the first to provide a review:

Write a Review

Average Ratings 0 Ratings

Total
ease
features
design
support

No User Reviews. Be the first to provide a review:

Write a Review

Description

BenevolentAI is a pioneering platform that leverages artificial intelligence and scientific technology to enhance drug discovery processes, specifically targeting complex diseases by efficiently processing and interpreting extensive biomedical data to yield actionable insights more swiftly than conventional approaches. By utilizing its unique Benevolent Platform, the company seamlessly integrates both structured and unstructured biomedical information—spanning literature, genomics, clinical data, and multi-omics—into a detailed knowledge graph. This robust framework empowers researchers to analyze biological systems, formulate testable hypotheses, identify new drug targets, and create potential drug candidates with increased confidence and reduced failure rates, ultimately transforming the landscape of medicine development. With its innovative approach, BenevolentAI stands at the forefront of a new era in the pharmaceutical industry.

Description

Pharmaceutical companies require extensive genomic data to effectively implement precision medicine initiatives; however, they frequently rely on merely 10% of the available information for their decisions. Genomenon provides access to the complete dataset. Their Prodigy™ Patient Landscapes offer a streamlined and economical solution for natural history research, aiding the creation of therapies for rare diseases by deepening understanding of both retrospective and prospective health data. Utilizing an advanced AI-driven methodology, Genomenon conducts a thorough evaluation of each patient documented in the medical literature in a significantly reduced timeframe. Ensure you capture all relevant insights by exploring every genomic biomarker featured in published studies. Each scientific claim is substantiated by concrete evidence drawn from the medical literature, allowing researchers to uncover all genetic drivers and identify variants recognized as pathogenic in accordance with ACMG clinical standards, thereby enhancing the development process of targeted therapies. By leveraging this comprehensive approach, pharma companies can enhance their research effectiveness and ultimately improve patient outcomes.

API Access

Has API No 

API Access

Has API Yes 

Screenshots View All

Screenshots View All

Integrations

Google Cloud Platform No 

Integrations

Google Cloud Platform Yes 

Pricing Details

No price information available.
Free Trial No 
Free Version No 

Pricing Details

No price information available.
Free Trial No 
Free Version No 

Deployment

Web-Based Yes 
On-Premises No 
iPhone App No 
iPad App No 
Android App No 
Windows No 
Mac No 
Linux No 
Chromebook No 

Deployment

Web-Based Yes 
On-Premises No 
iPhone App No 
iPad App No 
Android App No 
Windows No 
Mac No 
Linux No 
Chromebook No 

Customer Support

Business Hours Yes 
Live Rep (24/7) No 
Online Support Yes 

Customer Support

Business Hours Yes 
Live Rep (24/7) No 
Online Support Yes 

Types of Training

Training Docs Yes 
Webinars No 
Live Training (Online) Yes 
In Person No 

Types of Training

Training Docs Yes 
Webinars Yes 
Live Training (Online) Yes 
In Person Yes 

Vendor Details

Company Name

BenevolentAI

Founded

2013

Country

Luxembourg

Website

www.benevolent.com

Vendor Details

Company Name

Genomenon

Country

United States

Website

www.genomenon.com/pharma/

Alternatives

Alternatives

VSClinical Reviews

VSClinical

Golden Helix
Scitara DLX Reviews

Scitara DLX

Scitara